BioCentury
ARTICLE | Company News

Algen Biopharmaceuticals, BioLineRx deal

May 23, 2011 7:00 AM UTC

BioLineRx acquired exclusive rights to cancer candidate BL-7030 from Algen. The double-stranded RNA vector targeting EGFR is in preclinical testing. Algen has rights from the Hebrew University of Je...